Reset filter
Palavras-chave
HEMATOLOGIJA ×
Mostrar mais Palavras-chave
Índice
  1. 1. Estudo clínico
  2. 2. Documentação de rotina
  3. 3. Estudos de registo/coortes
  4. 4. Garantia da qualidade
  5. 5. Padrão de dados
  6. 6. Questionário do paciente
  7. 7. Especialidade médica
Modelos de dados selecionados

Deve ter sessão iniciada para selecionar vários modelos de dados e para os transferir ou analisar.

1099 Resultados da pesquisa.
Relevância Avaliação Novos primeiro Antigos primeiro

Patient Admision Pediatric Hematology and Oncology UK Muenster

- 20/09/2021 - 1 Formulário, 18 Grupos de itens, 195 Elementos de dados, 2 Idiomas
Grupos de itens: Patient, Father, Mother, Living arrangement, Sibling, Medical history, Nursing support, Support device, Personal aids, School, Kindergarten, workshop, Therapies in school, kindergarten, workshop, Medication, Medication history, Therapy, Nutrition, Continence, Catheters and drainages, Other
Freigabe zur Verarbeitung durch Frau Prof. Rössig, Quellenangabe: "Pädiatrische Hämatologie und Onkologie, UKM" Klinik für Kinder- und Jugendmedizin, Universitätsklinikum Münster Released for adaption by Frau Prof. Rössig Source:Pediatric Hematology und Oncology, University hospital Münster

Iodine 131 B1 Antibody for B-Cell Lymphomas NCT00950755 - History of Lymphoma

- 20/09/2021 - 1 Formulário, 5 Grupos de itens, 21 Elementos de dados, 1 Idioma
Grupos de itens: Administrative Data, Cell Type, Grade, Extranodal Involvement at Enrollment, CD20 Reactivity
Study ID: 104505 Clinical Study ID: BEX104505 Study Title: Phase II Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00950755 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: tositumomab Trade Name: Bexxar Study Indication: Lymphoma, Non-Hodgkin

Safety and Activity of SRT501 Alone or in Combination with Bortezomib in Patients with Multiple Myeloma NCT00920556 - Screening - Demography; Inclusion Criteria; Exclusion Criteria

- 20/09/2021 - 1 Formulário, 4 Grupos de itens, 34 Elementos de dados, 1 Idioma
Grupos de itens: Administrative, Demography, Inclusion Criteria, Exclusion Criteria
Study ID: 113222 Clinical Study ID: 113222 Study Title: A Phase II, Open Label, Clinical Study to Assess the Safety and Activity of SRT501 Alone or in Combination with Bortezomib in Patients with Multiple Myeloma Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00920556 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name:5.0g SRT501 Trade Name: Bortezomib Study Indication: Multiple Myeloma

Eligibility Lymphoma NCT02056548

- 20/09/2021 - 1 Formulário, 2 Grupos de itens, 12 Elementos de dados, 1 Idioma
Grupos de itens: Inclusion Criteria, Exclusion Criteria
Hepatitis B Virus Reactivation After Withdrawal of Preemptive Antiviral Therapy in Hematologic Malignancy; ODM derived from: https://clinicaltrials.gov/show/NCT02056548

Eligibility Lymphoma NCT02392039

- 20/09/2021 - 1 Formulário, 2 Grupos de itens, 11 Elementos de dados, 1 Idioma
Grupos de itens: Inclusion Criteria, Exclusion Criteria
Study of Loratadine for Pegfilgrastim Induced Bone Pain in Patients With Aggressive Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT02392039

Visit 1 Ponderosa CML ZKSJ0083 - Visit 1

- 20/09/2021 - 1 Formulário, 11 Grupos de itens, 191 Elementos de dados, 1 Idioma
Grupos de itens: Inclusion Criteria, Exclusion Criteria, Informed consent, Demographics, Myeloid Leukemia, Chronic, therapy CML, Patient medical history, medical history, Blood pressure, Laboratory parameters, Treatment
Study part: Visit 1.Observational study on CML patients in any phase treated with ponatinib (Iclusig®) at any dose. Principal Investigator Prof. Dr. A. Hochhaus.

MDS Register Düsseldorf

- 20/09/2021 - 1 Formulário, 15 Grupos de itens, 189 Elementos de dados, 1 Idioma
Grupos de itens: Administrative data, Symptoms at initial diagnosis, Comorbidity at initial diagnosis, Comorbidity Follow up, Laboratory at initial diagnosis, Laboratory follow-up, Follow up, Disease progression, Blood cell morphology, Cellular Morphology Bone marrow, Histology Bone Marrow, Molecular Genetics, secondary myelodysplastic syndromes, Therapy Myelodysplastic syndrome, Treatment
Documentation for MDS Register Düsseldorf. Provided by Prof. Gattermann, Author: Prof. Germing.

Arm A / SIRT SirTac NCT02936388 - Arm A / SIRT

- 20/09/2021 - 1 Formulário, 3 Grupos de itens, 21 Elementos de dados, 1 Idioma
Grupos de itens: Diagnostic procedure, selective internal radiation therapy, Adverse Events
Study part: Arm A / SIRT. A Randomized Phase II Trial of Transarterial Radioembolisation With Yttrium-90 (SIRT) in Comparison to Transarterial Chemoembolisation With Cisplatin (TACE) in Patients With Liver Metastases From Uveal Melanoma. Provided by Prof. Dr. Ulrich Keilholz, Charité – University of medicine Berlin. EudraCT-Nummer: 2014-002439-32. NCT02936388.

Arm B / TACE SirTac NCT02936388 - Arm B / TACE

- 20/09/2021 - 1 Formulário, 2 Grupos de itens, 23 Elementos de dados, 1 Idioma
Grupos de itens: study group, Adverse Events
Study part: Arm B / TACE. A Randomized Phase II Trial of Transarterial Radioembolisation With Yttrium-90 (SIRT) in Comparison to Transarterial Chemoembolisation With Cisplatin (TACE) in Patients With Liver Metastases From Uveal Melanoma. Provided by Prof. Dr. Ulrich Keilholz, Charité – University of medicine Berlin. EudraCT-Nummer: 2014-002439-32. NCT02936388.

Eligibility Multiple Myeloma NCT00642395

- 20/09/2021 - 1 Formulário, 2 Grupos de itens, 21 Elementos de dados, 1 Idioma
Grupos de itens: Inclusion Criteria, Exclusion Criteria
Velcade®-Melphalan Association in Autologous Stem-Cell Transplantation (ASCT); ODM derived from: https://clinicaltrials.gov/show/NCT00642395

Eligibility Multiple Myeloma NCT00590603

- 20/09/2021 - 1 Formulário, 2 Grupos de itens, 11 Elementos de dados, 1 Idioma
Grupos de itens: Inclusion Criteria, Exclusion Criteria
Trisenox, Ascorbic Acid and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma; ODM derived from: https://clinicaltrials.gov/show/NCT00590603

Present aftercare Physician’s questionnaire for aftercare ABC study - Present aftercare Physician’s questionnaire for aftercare

- 20/09/2021 - 1 Formulário, 11 Grupos de itens, 99 Elementos de dados, 1 Idioma
Grupos de itens: Administrative, Medical Examination, Medical consultation, laboratory tests, Aftercare, medical consultation early cancer prevention, vaccination status, cardiovascular risk factor, Rehabilitation measures, Physical therapy, Medication
Study part: Present aftercare Physician’s questionnaire for aftercare ABC Study. Aftercare pattern in adult patients with blood cancer and blood cancer early stage: Impact on health related endpoints, quality of life and health resource use. University clinic essen, (Klinik für Hämatologie Uniklinik Essen, UKE), department hematology. Permission granted by Claudia Ose.

Ajuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial